Pivotal US Patent Protecting Resomelagon (AP1189) Granted to SynAct Pharma
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
SynAct Pharma AB (publ) (“SynAct”) (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnology company focused on resolving inflammation through selective activation of the melanocortin system, announced that today, March 4, 2025, the United States Patent and Trademark Office (USPTO) has issued US patent 12,239,631 with claims covering the crystal form of resomelagon (AP1189) currently undergoing development in clinical phase 2b.
The US patent is a major cornerstone in the strategy to further protect SynAct’s intellectual property rights with respect to resomelagon and will add to the layers of protection ensuring exclusivity in the US of its lead asset as composition of matter until 2042.
“We are thrilled by this news which supports that we have laid out a successful patent strategy for resomelagon. A composition of matter patent for a crystal form of a drug candidate will apply irrespective of how the claimed solid is formulated or used, and thus it is a very broad and strong patent”, said Thomas Boesen, COO at SynAct.
Resomelagon, currently in Phase 2b clinical development in Rheumatoid Arthritis, is administered in a specific salt form. During the development of the drug candidate, SynAct prepared a crystal form of this specific salt and discovered associated favorable properties. The patent that has now issued by the USPTO is the first in its extended family of patent applications in all major markets around the globe. SynAct continues to pursue additional patent families to further enhance its existing patent estate protecting aspects of resomelagon.
“To obtain patent coverage of resomelagon as composition of matter in a major market like the US is very important for us, our potential partners and the future value of developing AP1189 as a drug”, said Jeppe Øvlesen, CEO at SynAct. “With this patent, we will tick off yet another check box, making our lead asset even more attractive, extending our exclusive rights by several years beyond projected market entry and thus expanding our impact in the area of resolution of inflammation”.